Ernexa Therapeutics Inc. Income (Loss) from Continuing Operations, Per Basic Share
Ernexa Therapeutics Inc. (ERNA) reported Income (Loss) from Continuing Operations, Per Basic Share of $0.01 per share for the 3-month period ending 2012-12-31, per its 10-K filed 2013-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2013-03-29
- Ernexa Therapeutics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2012-12-31 was $0.01.
- Ernexa Therapeutics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2012-09-30 was $0.00.
- Ernexa Therapeutics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2012-06-30 was -$0.01.
- Ernexa Therapeutics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2012-03-31 was -$0.02.
- Ernexa Therapeutics Inc. income (loss) from continuing operations, per basic share for fiscal 2012 was -$0.01.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|
| 2012-12-31 | $0.01 10-K · filed 2013-03-29 | -$0.01 10-K · filed 2013-03-29 |
| 2012-09-30 | $0.00 10-K · filed 2013-03-29 | |
| 2012-06-30 | -$0.01 10-K · filed 2013-03-29 | |
| 2012-03-31 | -$0.02 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |